卡非佐米治疗多发性骨髓瘤临床应用指导原则(2024年版)  

Chinese guideline principles for clinical application of carfilzomib in multiple myeloma(2024 version)

作　　者：中国临床肿瘤学会(CSCO)多发性骨髓瘤专家委员会 贡铁军[3] 刘彤[2] 马军[3] 邱录贵 Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun;Qiu Lugui(不详;Harbin Institute of Hematology and Oncology,Harbin 150010,China;State Key Laboratory of Experimental Hematology,National Clinical Medical Research Center for Blood Diseases,Institute of Hematology&Blood Diseases Hospital,China Academy of Chinese Medical Sciences,Tianjin 300020,China)

机构地区：[1]不详 [2]天津医科大学第二医院 [3]哈尔滨血液病肿瘤研究所,哈尔滨150010 [4]中国医学科学院血液病医院(中国医学科学院血液学研究所),实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心细胞生态海河实验室,天津300020

出　　处：《白血病．淋巴瘤》2024年第10期577-586,共10页Journal of Leukemia & Lymphoma

摘　　要：以蛋白酶体抑制剂为基础的联合方案已经成为多发性骨髓瘤(MM)治疗方案的重要组成。卡非佐米作为新一代蛋白酶体抑制剂,具有高选择性、不可逆结合的四肽环氧酮结构,于2012年被美国食品药品监督管理局(FDA)批准用于复发或难治MM患者,随后多种卡非佐米联合方案陆续获批。2021年7月卡非佐米在中国获批上市,为我国MM患者提供了新的治疗手段。为进一步规范卡非佐米的临床应用,专家组参考近年国内外研究进展及权威指南,制定了卡非佐米治疗MM的临床应用指导原则,旨在为我国临床医师用药提供参考。Proteasome inhibitors-based combination therapy has become an important treatment component for multiple myeloma(MM).Carfilzomib,as a new generation proteasome inhibitor,possesses high selectivity and irreversibly binds with a tetrapeptide epoxide structure.It was approved by the U.S.Food and Drug Administration(FDA)in 2012 for relapsed/refractory MM patients,and subsequently,various combination regimens have been approved.In July 2021,carfilzomib obtained market approval in China,providing a new treatment option for MM patients.To further standardize the clinical application of carfilzomib,a panel of experts formulated this Chinese guideline principles for the clinical application of carfilzomib by referring to recent domestic and international research progresses and authoritative guidelines,in order to provide references for Chinese clinicians.

关 键 词：多发性骨髓瘤 卡非佐米 新一代蛋白酶体抑制剂 不可逆抑制 

分 类 号：R733.3[医药卫生—肿瘤]